MARKET

RETA

RETA

Reata Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

91.20
+0.33
+0.36%
After Hours: 91.20 0 0.00% 16:21 04/19 EDT
OPEN
90.22
PREV CLOSE
90.87
HIGH
92.15
LOW
87.79
VOLUME
251.77K
TURNOVER
--
52 WEEK HIGH
186.82
52 WEEK LOW
84.17
MARKET CAP
3.30B
P/E (TTM)
-11.3808
1D
5D
1M
3M
1Y
5Y
High Blood Pressure Drugs (Hypertension) Market Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2028 By Ameco Research
pune, India, Mon, 19 Apr 2021 23:31:08 / Comserve Inc. / -- The global High Blood Pressure Drugs (Hypertension) market is segmented by company, region...
Comserve · 3h ago
Global Diabetic Peripheral Neuropathy Treatment Market Share 2021, Different Regions, Product Overview and Size, Impact of COVID-19 Analysis, Company Profiles, Growth Factors, Product Demand, Opportunities till 2026
Apr 19, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry" Global “Diabetic Peripheral Neuropathy...
The Express Wire · 22h ago
8-K: REATA PHARMACEUTICALS INC
(EDGAR Online via COMTEX) -- false 0001358762 0001358762 2021-04-15 2021-04-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 4d ago
BRIEF-Reata Announces The Appointments Of Christy Oliger And Shamim Ruff To Its Board Of Directors
reuters.com · 4d ago
Reata Announces the Appointments of Christy J. Oliger and Shamim Ruff to Its Board of Directors
PLANO, Texas, April 15, 2021 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointments of Christy J. Oliger and Shamim Ruff to its Board of...
GlobeNewswire · 4d ago
Mitochondrial Myopathy Diagnosis & Treatment Market Share, Size ,Growth Opportunities, Global Competition Strategies, Statistics, Industry Trends, Revenue Analysis, Key Players and Regional Analysis
The Express Wire · 5d ago
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13)
Benzinga · 5d ago
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12)
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RETA. Analyze the recent business situations of Reata Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RETA stock price target is 243.38 with a high estimate of 322.00 and a low estimate of 200.00.
EPS
Institutional Holdings
Institutions: 315
Institutional Holdings: 26.94M
% Owned: 74.40%
Shares Outstanding: 36.20M
TypeInstitutionsShares
Increased
69
3.25M
New
49
828.28K
Decreased
65
1.20M
Sold Out
30
389.53K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.60%
Pharmaceuticals & Medical Research
-0.26%
Key Executives
Chairman/President/Chief Executive Officer/Director
J. Warren Huff
Chief Financial Officer/Chief Operating Officer/Executive Vice President
Manmeet Soni
Executive Vice President
Dawn Bir
Executive Vice President
Colin Meyer
Executive Vice President
Michael Wortley
Chief Technology Officer/Vice President
Kevin Johnston
Vice President
Andrea Loewen
Other
Seemi Khan
Director
Christy Oliger
Director
Shamim Ruff
Independent Director
Martin Edwards
Independent Director
William McClellan
Independent Director
R. Kent McGaughy
Independent Director
Jack Nielsen
Independent Director
William Rose
No Data
About RETA
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.

Webull offers kinds of Reata Pharmaceuticals Inc stock information, including NASDAQ:RETA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RETA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RETA stock methods without spending real money on the virtual paper trading platform.